Good news? Another medical breakthrough? Or Enhanced profits for Drug Companies?
Weight-Loss drugs (Ozempic, Wygovy, Mounjaro, et al) are the new in-thing! Everyone, it would appear, wants them in order to lose weight. Yet these drugs are not safe. In September 2025 it was reported that the first deaths had been reported, one death per week, according to the Sun newspaper. You will see that several large mainstream media outlets did report this, which was most unusual.Even the Conventional Medical Establishment has safety worries about these weight-loss drugs, saying they need to be taken under medical supervision, and their use restricted to people who have a clinical need for them - owing to the risk of potentially serious adverse reactions.
But none of this has limited an almost insatiable demand for the drugs. So people who cannot obtain them through normal health service channels are buying the drugs privately, on the internet, some of them, reputedly are ‘fake’ drugs, and thought to be even more dangerous.
So perhaps when Medscape reported that there was a new drug, NG101, that eases the side effects of weight-loss drugs it is good news? Medscape claimed that research showed that NG101“reduced nausea and vomiting in patients with obesity by 40% and 67% respectively”. However, the article fails to address 5 points.
The research, even if does not exaggerate the data, means that 60% of users of weight-loss drugs who suffer nausea will continue to suffer nausea; and 33% of users who suffer vomiting will continue to suffer vomiting.
Nausea and vomiting are two of the least serious ‘side effects’ of these drugs; certainly less serious than death; and perhaps less serious than some of the other ‘side effects’ admitted by conventional medicine, which include anxiety, blurred vision, confusion, constipation, diarrhoea, depression, fever, headache, indigestion, nightmares, seizures, tightness in the chest, trouble breathing, unusual tiredness or weakness, acid/sour stomach, heartburn, and much more.
The announcement is typical of pharmaceutical companies business plans, that is, to market and promote a drug which causes serious patient harm, and then to introduce another drug that ‘eases’ some of that patient harm cause by the first drug. A remarkable, and often-used business creation scheme!
Any side effects of the new drug, NG101, were (as usual) discounted! “No serious adverse events related to the study drug were reported in either group”. However, I am sure that we can expect that drug companies will now be looking for another drug, another business opportunity, to counter the side effects of NG101.
The study was funded by Neurogastric (and I will assume that NG101 is a product of this company). The author of the study, Sean Wharton, disclosed that he served as a consultant for Neurogastrix but did not declare that he was an investigator in the study.
And so on it goes. Medical breakthroughs are regularly announced by drug companies that are not medical breakthroughs. Here, the problem of obesity, caused largely by diet, but also by pharmaceutical drugs, is reaching epidemic proportions, and the pharmaceutical industry is seeking to enrich themselves.